3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 2
3
Phase 3
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
70
Lymphoma
54
Lymphoma, Large B-Cell, Diffuse
40
Precursor Cell Lymphoblastic Leukemia-Lymphoma
29
Hodgkin Disease
26
Sarcoma
25
Lymphoma, Follicular
25
Lymphoma, Non-Hodgkin
24
Leukemia
19
Burkitt Lymphoma
17
Multiple Myeloma
16
Endometrial Neoplasms
15
Neuroblastoma
14
Ovarian Neoplasms
12
Carcinoma, Hepatocellular
12
Lymphoma, Large-Cell, Immunoblastic
11
Lymphoma, Mantle-Cell
10
Liposarcoma
9
Neoplasms
8
Lymphoma, Large-Cell, Anaplastic
8
Leiomyosarcoma
8
Histiocytoma, Malignant Fibrous
8
Urinary Bladder Neoplasms
7
Lymphoma, B-Cell, Marginal Zone
7
Hemangiosarcoma
7
Fibrosarcoma
7
Wilms Tumor
6
Triple Negative Breast Neoplasms
6
Sarcoma, Synovial
6
Neurofibrosarcoma
6
Interventions
Etoposide
34
Carboplatin
31
Topotecan
24
Cisplatin
21
atezolizumab
11
PM 01183
8
durvalumab
7
Irinotecan
7
amrubicin
5
PE regimen
4
AMG 757
4
rovalpituzumab tesirine
3
pembrolizumab
3
Magnetic Resonance Spectroscopy
3
Dexamethasone
3
tremelimumab
2
tislelizumab
2
etoposide phosphate
2
apatinib
2
Vitamin E
2
Tiragolumab
2
Specimen Handling
2
Radiosurgery
2
RRx-001
2
Paclitaxel
2
Memantine
2
Injections
2
EC regimen
2
trilaciclib
1
toripalimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Small Cell Lung Carcinoma
×
Doxorubicin
×
Clear all
NCT02566993
2021-10-28
ATLANTIS
PharmaMar
Phase 3
Completed
613 enrolled
46 charts